Studies have shown that combining TTZ with chemotherapy improves complete response rates, long-term survival, and event-free survival in HER2-positive breast cancer patients, both in neoadjuvant and adjuvant settings [10,11]. Here, ERBB2 is linked to breast carcinoma.